
Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund.
The oversubscribed fund is positioned to have a transformative impact on the field of mental health by funding a diverse portfolio of businesses developing innovative psychedelic medicines and therapies targeting both mental health as well as a range of Central nervous system (CNS) disorders.